Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds › C07D 401 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
Patents for C07D 401 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom (107,979)
11/2005
11/23/2005CN1699342A New hydroxyindoles, their use as phosphodiesterase 4 inhibitors and method for producing same
11/23/2005CN1698601A Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl iv, processes for their preparation, and their use
11/23/2005CN1228338C Imidazole derivatives or salts thereof and drugs contg. derivatives or salts
11/23/2005CN1228327C Carboxylic acid derivatives and drugs containing the same
11/22/2005US6967254 Substituted heterocyclic compounds and methods of use
11/22/2005US6967253 Method for synthesis of 5-(3-pyridylmethylene-)imidazolidine-2,4-dione
11/22/2005US6967252 Comprising a sterically hindered nitroxyl, hydroxylamine or hydrocarbyloxyamine moiety and a organohalogen or organophosphorus flame retardant moiety; polymer molding substrates; synergistic; nondripping; air pollution control
11/22/2005US6967251 Reagents for labeling biomolecules having aldehyde or ketone moieties
11/22/2005US6967210 Multiple sclerosis, brain disorders, analgesics
11/22/2005US6967208 Anticoagulants; cardiovascular disorders
11/22/2005US6967205 Compounds with antibacterial and antiparasitic properties
11/22/2005CA2258918C Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
11/22/2005CA2109697C Oral-administration forms of a medicament containing pantoprazole
11/17/2005WO2005108391A1 Amides as bace inhibitors
11/17/2005WO2005108390A1 Indol-2-one derivatives for the treatment of central nervous disorders, gastrointestinal disorders and cardiovascular disorders
11/17/2005WO2005108389A1 Indole derivatives having piperidine rings
11/17/2005WO2005108388A1 Pyridine derivatives of alkyl oxindoles as 5-ht7 receptor active agents
11/17/2005WO2005108387A2 Cytokine inhibitors
11/17/2005WO2005108374A1 Insecticidal diazole and triazole derivatives
11/17/2005WO2005108373A1 Novel beta agonists, method for producing the same and their use as drugs
11/17/2005WO2005108370A1 Benzene compounds
11/17/2005WO2005108367A1 Compounds for treatment of neurodegenerative diseases
11/17/2005WO2005108364A1 Piperazine derivatives of alkyl oxindoles
11/17/2005WO2005108359A1 Novel compounds of proline and morpholine derivatives
11/17/2005WO2005108358A2 Pyrrolidine derivatives useful as bace inhibitors
11/17/2005WO2005107758A1 4-phenylamino-quinazolin-6-yl-amides
11/17/2005WO2005096692A3 Crystalline forms of mizolastine, production methods thereof and pharmaceutical compositions containing same
11/17/2005WO2005085177A3 Biaryl amino acids and their use in dna binding oligomers
11/17/2005WO2005058834A3 Quinolines useful in treating cardiovascular disease
11/17/2005WO2005051906A3 Heterocyclic inhibitors of mek and methods of use thereof
11/17/2005WO2005030751A3 Dipeptidyl peptidase inhibitors
11/17/2005WO2004111029A3 Process for preparing 2-[(pyridinyl)methyl]sulfinyl-substituted benzimidazoles and novel chlorinated derivatives of pantoprazole
11/17/2005WO2004082602A3 Carboxamide spirohydantoin cgrp receptor antagonists
11/17/2005US20050256315 1h-benzo{f}indazol-5-yl derivatives as selective glucocorticoid receptor modulators
11/17/2005US20050256311 Pyrimidine compounds
11/17/2005US20050256310 Therapeutic compounds
11/17/2005US20050256309 Tri-and bi-cyclic heteroaryl histamine-3 receptor ligands
11/17/2005US20050256180 drugs such as 1 -[4-(aminosulfonyl)phenyl]-8-{[(trifluoromethyl)sulfonyl]amino}-4,5-dihydro-1H-benzo[g]indazole-3-carboxamide, used as antiinflammatory agents, antiarthritic agents, antipyretics or analgesics
11/17/2005US20050256176 Sulphonamide derivatives and their use as tace inhibitors
11/17/2005US20050256171 Pyrrolidine derivatives as tryptase inhibitors
11/17/2005US20050256170 EP receptor (for which the endogenous ligand is prostaglandin E2, PGE2); e.g. (4-[(5-Phenyl-furan-2-carbonyl)-amino]-phenyl)-acetic acid or 5-Phenyl-furan-2-carboxylic acid [3-(1H-tetrazol-5-yl)-phenyl]-amide; dysmenorrhoea, preterm labour, glaucoma, immune disorders, inflammatory disorders
11/17/2005US20050256167 Preparation and use of imidazole derivatives for treatment of obesity
11/17/2005US20050256166 Nitrogen-containing compounds
11/17/2005US20050256164 NK1 and NK3 antagonists
11/17/2005US20050256160 Beta-alanine derivatives and the use thereof
11/17/2005US20050256159 1,4-disubstituted piperidine derivatives and their use as 11,betahsd1 inhibitors
11/17/2005US20050256158 PGD2 receptor antagonists for the treatment of inflammatory diseases
11/17/2005US20050256155 e.g. (3S,4aR,6R,8aR)-6-[2-(1H-Tetrazol-5-yl)-ethyl]-1,2,3,4,4a,5,6,7,8,8a-decahydro-isoquinoline-3-carboxylic acid 2-ethyl-butyl ester trifluoroacetate salt; are substantially converted to the parent monoacid in the patient; AMPA glutamate receptor antagonists
11/17/2005US20050256145 Pyrimidine derivatives for the treatment of abnormal cell growth
11/17/2005US20050256144 Selective inhibitors of certain receptor and non-receptor tyrosine kinases such as FAK (focal adhesion kinase); anticancer agents; N-{1-[2-(2-Oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-yl]-piperidin-4-yl}-methanesulfonamide for example
11/17/2005US20050256137 Pyridone compounds as inhibitors of bacterial type III protien secreation systems
11/17/2005US20050256136 1-[2-(3-Ethyl-ureido)-3H-benzoimidazol-5-yl]-1H-imiazole-4-carboxylic acid methyl ester; bacteriostatic antibiotic; decrease antibiotic resistance of bacterial organisms; new class of compounds for bacterial infections
11/17/2005US20050256132 Use of ER selective NF-kB inhibitors for the treatment of sepsis
11/17/2005US20050256130 Substituted piperazines
11/17/2005US20050256126 for treatment of microbial infections; potent inhibitors of (bMAP) bacterial aminopeptidase
11/17/2005US20050256124 Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto
11/17/2005US20050256123 Heterocyclic inhibitors of MEK and methods of use thereof
11/17/2005US20050256122 Substituted pyridazinones
11/17/2005US20050256120 Heterocyclo-substituted imidazoles for the treatment of inflammation
11/17/2005US20050256118 Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
11/17/2005US20050256117 Ophthalmic compositions for treating ocular hypertension
11/17/2005US20050256113 Anti-cytokine heterocyclic compounds
11/17/2005US20050256111 Pyrimidine derivatives for the treatment of abnormal cell growth
11/17/2005US20050256106 Such as 1-phenylsulfonyl-4-piperazinylindole hydrochloride for treatment or prophylaxis of disease mediated by serotonin related receptor, obesity, and/or central nervous system disorder
11/17/2005US20050256104 Protease inhibitors
11/17/2005US20050256103 Indole derivative having piperidine ring
11/17/2005US20050256099 Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
11/17/2005US20050256098 CGRP receptor antagonists
11/17/2005US20050256089 for use as pesticides, herbicides; condensation
11/17/2005US20050256066 Fredericamycin derivatives
11/17/2005US20050256003 Novel herbicides
11/17/2005US20050256000 Quinoxalin-2-one derivatives, compositions which protect useful plants and comprise these derivatives, and processes for their preparation and their use
11/17/2005US20050255528 Amine-reactive quaternary acridinium compounds, e.g., pentafluorophenyloxy-1-carbonyl-4,7,10,13-tetraoxapentadecyl-(15-amino)-3'-sulfonyl-2',6'-dimethylphenyl-N-(3-sulfopropyl)-acridinium-9-carboxylate with increased solubility; chemiluminescent conjugates, especially with antibodies; assay kits
11/17/2005US20050255465 Novel fluorescent label compounds
11/17/2005DE102004020186A1 Heterocyclylessigsäuren als Inhibitoren von TAFla Heterocyclylessigsäuren as inhibitors of TAFIa
11/17/2005DE102004018953A1 4-Halogenalkylpyridin-3-sulfonsäureamide, Verfahren zu ihrer Herstellung, sie enthaltende Mittel und ihre Verwendung als Schädlingsbekämpfungsmittel 4-haloalkylpyridine-3-sulfonamides, process for their preparation, compositions containing them and their use as pesticides
11/17/2005CA2566426A1 Indol-2-one derivatives for the treatment of central nervous disorders, gastrointestinal disorders and cardiovascular disorders
11/17/2005CA2566096A1 Piperazine derivatives of alkyl oxindoles
11/17/2005CA2565843A1 Novel compounds of proline and morpholine derivatives
11/17/2005CA2565061A1 Pyridine derivatives of alkyl oxindoles as 5-ht7 receptor active agents
11/17/2005CA2564980A1 Novel beta agonists, method for producing the same and their use as drugs
11/17/2005CA2560387A1 Cytokine inhibitors
11/16/2005EP1595880A1 Crystalline forms of a pyridinyl-sulfonamide and their use as endothelin receptor antagonists
11/16/2005EP1595879A2 Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
11/16/2005EP1595878A1 Indole derivatives with apoptosis inducing activity
11/16/2005EP1595871A2 Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
11/16/2005EP1595869A1 Pyrimidine derivatives
11/16/2005EP1595867A1 Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient
11/16/2005EP1594938A1 Electrochromic compounds
11/16/2005EP1594863A1 Tri(cyclo) substituted amide glucokinase activator compounds
11/16/2005EP1594861A1 Triazole compounds and the therapeutic use thereof
11/16/2005EP1594860A2 Library of biphenyl derivatives useful for identifying compounds having both beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
11/16/2005EP1594859A1 Indazolamides with analgesic activity
11/16/2005EP1594858A2 Novel benzoimidazole derivatives useful as antiproliferative agents
11/16/2005EP1594848A1 Aryl acid pyrimidinyl methyl amides, pyridazinyl methyl amides and related compounds
11/16/2005EP1594847A2 Substituted azole derivatives as therapeutic agents
11/16/2005EP1594845A2 Benzene acetamide compounds useful as serine protease inhibitors
11/16/2005EP1594841A1 Vegfr-2 and vegfr-3 inhibitory anthranylamidopyridines
11/16/2005EP1594840A1 Piperidine-benzenesulfonamide derivatives
11/16/2005EP1594505A2 Phenylglycine derivatives useful as serine protease inhibitors
1 ... 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 ... 1080